Shares of CVS Health Corp (NYSE:CVS) ended Friday session in green amid volatile trading. The shares closed up +0.47 points or 0.50% at $93.84 with 3.13 million shares getting traded. Post opening the session at $93.83, the shares hit an intraday low of $93.52 and an intraday high of $94.20 and the price vacillated in this range throughout the day. The company has a market cap of $100.02 billion and the numbers of outstanding shares have been calculated to be 1.07 billion shares.
CVS Health Corp (CVS) announced that Larry Merlo, the company’s president and chief executive officer, will be speaking to investors at the Morgan Stanley Global Healthcare Conference on September 13, 2016, at approximately 8:00 a.m. ET.
An audio webcast of the event will be broadcast simultaneously on the Investor Relations portion of the CVS Health website for all interested parties, and will be archived and available for a one-year period. To access the webcast or an archive of the event, visit http://investors.cvshealth.com.
Shares of GlaxoSmithKline plc (ADR) (NYSE:GSK) ended Friday session in green amid volatile trading. The shares closed up +1.28 points or 2.98% at $44.26 with 3.92 million shares getting traded. Post opening the session at $43.89, the shares hit an intraday low of $43.76 and an intraday high of $44.46 and the price vacillated in this range throughout the day. The company has a market cap of $104.33 billion and the numbers of outstanding shares have been calculated to be 4.87 billion shares.
On Aug. 16, 2016 ViiV Healthcare announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy.
The phase III programme comprises two identical studies (GEMINI 1 and 2) comparing a two-drug regimen of dolutegravir plus lamivudine with a three-drug regimen of dolutegravir plus the fixed-dose tablet tenofovir/emtricitabine (Truvada®). The studies together will include approximately 1,400 men and women living with HIV and are being conducted at research centres in Europe, Central and South America, North America, South Africa and Asia Pacific.
HIV care is a long-term prospect for those living with the disease, requiring life-long adherence to treatment. Since the introduction of highly active antiretroviral therapy 20 years ago, HIV treatment regimens have predominantly included three antiretroviral drugs., ViiV Healthcare is looking to the future and exploring how HIV treatment could evolve to reduce drug exposure and improve treatment adherence, while maintaining the level of efficacy achieved with three-drug regimens.
John C Pottage, Jr, MD, Chief Scientific and Medical Officer, ViiV Healthcare, commented, “We believe the clinical profile for dolutegravir presents an important opportunity to investigate the possibility of first-line treatment of HIV with a two-drug regimen. With this ambitious phase III programme, we will explore whether this two-drug regimen can fundamentally change the existing HIV treatment strategy, reducing the number of medications and potentially streamlining treatment regimens for people living with HIV.”